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Abstract  
 
Objective: Thrombin is the key serine protease of the coagulation cascade and mediates 
cellular responses by activation of protease-activated receptors (PARs). The 
predominant thrombin receptor is PAR1 and in endothelial cells (ECs) thrombin 
dynamically regulates a plethora of phosphorylation events. However, it has remained 
unclear if thrombin signaling is exclusively mediated through PAR1. Furthermore, 
mechanistic insight into activation and inhibition of PAR1-mediated EC signaling is 
lacking. In addition, signaling networks of biased PAR1 activation after differential 
cleavage of the PAR1 N-terminus have remained an unresolved issue. 
  
Approach and Results: Here, we used a quantitative phosphoproteomics approach to 
show that ‘classical’ and ‘peptide’ activation of PAR1 induce highly similar signaling, that 
low thrombin concentrations initiate only limited phosphoregulation, and that the PAR1 
inhibitors vorapaxar and parmodulin-2 demonstrate distinct antagonistic properties. 
Subsequent analysis of the thrombin-regulated phosphosites in presence of PAR1 
inhibitors revealed that biased activation of PAR1 is not solely linked to a specific G-
protein downstream of PAR1. In addition, we showed that only the canonical thrombin 
PAR1 tethered ligand induces extensive early phosphoregulation in ECs. 
 
Conclusions: Our study provides detailed insight in the signaling mechanisms 
downstream of PAR1. Our data demonstrates that thrombin-induced EC 
phosphoregulation is mediated exclusively through PAR1, that thrombin and thrombin-
TL peptide induce similar phosphoregulation and that only canonical PAR1 cleavage by 
thrombin generates a tethered ligand that potently induces early signaling. Furthermore, 
platelet PAR1 inhibitors directly affect EC signaling, indicating it will be a challenge to 
design a PAR1 antagonist that will target only those pathways responsible for tissue 
pathology. 
 
 
Nonstandard Abbreviations and Acronyms 
 
APC   Activated protein C  
BOEC Blood outgrowth endothelial cell 
EC  Endothelial cell 
GPCR G-protein coupled receptor 
MMP1 Matrix metalloproteinase-1 
NE  Neutrophil elastase 
PR3  Neutrophil protease 3 
PAR  Protease-activated receptor 
PLCB3 1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-3 
PRKD1 Serine/threonine-protein kinase D1 
STAT3 Signal transducer and activator of transcription 3 
TL  Tethered ligand 
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Introduction 
Thrombin is a plasma protein that functions as a key serine protease in the coagulation 
cascade by activating a variety of coagulation proteins and converting soluble fibrinogen 
into insoluble fibrin strands. In addition, thrombin mediates cellular responses by 
activation of protease-activated receptors (PARs), a family of four G-protein coupled 
receptors (GPCRs): PAR1, PAR2, PAR3 and PAR4. These receptors are activated by 
proteolytic cleavage of their extracellular N-terminus, resulting in the formation of a novel 
N-terminus that serves as a tethered ligand (TL) folding back into the ligand-binding 
pocket of the receptor.1,2 PARs are expressed on a large number of cells, including 
endothelial cells (ECs), platelets, monocytes, T lymphocytes, and smooth muscle cells.3 
The physiological role of PAR activation in hemostasis is linked to platelet and EC 
activation. Thrombin activation of platelets induces shape change and release of alpha-
granules, while thrombin activation of ECs leads to exocytosis of the von Willebrand 
Factor containing Weibel-Palade bodies and a decreased endothelial barrier function 
which promotes leukocyte extravasation.3–5 
 
Using quantitative phosphoproteomics, we unraveled the complex signaling pathway of 
thrombin in ECs, revealing thousands of dynamically regulated phosphorylation sites 
(phosphosites).6 While PAR1 is the predominant thrombin receptor in ECs, it has 
remained unclear whether the extensive thrombin-induced phosphoregulation is 
mediated exclusively via PAR1 or if other receptors, including PAR2, also contribute.7  
 
Like many GPCRs, PAR1 is subject to ligand-dependent preferential activation of 
downstream targets, a process known as biased signaling.8 Several mechanisms have 
been described9, including (1) enzymatic and peptide activation2,10–13, (2) PAR1 
inhibitor-induced differential G-protein activation14,15, (3) concentration dependent effects 
of thrombin16,17, (4) differential proteolytic cleaveage9,18–20 and (5) G-protein- versus 
beta-arrestins-mediated signaling.21,22 The molecular mechanism of these distinct 
modes of biased PAR1 activation have remained an unresolved issue. 
 
The most well-known mechanisms of PAR1 activation are enzymatic activation by 
thrombin and activation by soluble peptides that mimic the TL that is formed after N-
terminal proteolytic cleavage. It has been suggested that although thrombin-TL peptide 
(SFLLRN-NH2) mimics thrombin activation of PAR12,10, in comparison to thrombin it 
favors downstream activation of Gαq over Gα12/13.11–13 Therefore, it is still under debate 
whether ‘classical activation’ of PAR1 by thrombin and ‘peptide activation’ by thrombin-
TL peptide induce the same effects in ECs. 
 
Another form of biased PAR1 activation has been attributed to PAR1 inhibitors. Platelet 
PAR1 has become a target for anti-thrombotic therapies and several inhibitors have 
been developed that target PAR1.The orthosteric PAR1 inhibitor vorapaxar prevents 
activation of PAR1 by occupying the ligand-binding pocket23, and has recently been 
approved by the FDA.24 However, treatment with vorapaxar was associated with an 
increased bleeding risk24–26,which has been suggested to be linked to global inhibition of 
PAR1 on cells other than platelets, most notably ECs.27 New approaches to prevent 
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side-effects in targeting of PAR1 have led to the development of several allosteric PAR1 
inhibitors that target its cytoplasmic face (pepducins28,29 and parmodulins14,15). It has 
been suggested that parmodulin-2 promotes biased PAR1 signaling by preferentially 
blocking Gαq- over Gα12/13-mediated PAR1 signaling.15 However, detailed understanding 
of the global effects of PAR1 inhibition on ECs as well as the effect of PAR1 inhibitors 
on thrombin-mediated endothelial signaling is lacking. 
 
Recently, yet another mechanism of biased PAR1 has been described. In addition to 
PAR1 cleavage by thrombin (canonical PAR1 cleavage at Arg-41) several other 
proteases have been described to cleave PAR1 (non-canonical PAR1 cleavage), 
resulting in biased signaling in ECs.9 The cytoprotective effects of activated protein C 
(APC) are mediated via PAR1 (cleavage at Arg-46)18, and also Matrix 
metalloproteinase-1 (MMP1), Neutrophil elastase (NE) and Neutrophil protease 3 (PR3) 
are able to cleave the N-terminus of PAR1 in proximity to the canonical thrombin 
cleavage site19,20. However, little is known about the signaling networks that are 
activated after non-canonical cleavage of PAR1. Finally, thrombin itself has also been 
suggested to induce biased signaling in ECs depending on its concentration; at high 
concentrations (>100 pM) thrombin causes a barrier-disruptive response in ECs, 
whereas at low concentrations (50 pM) the effect of thrombin is believed to be barrier-
protective.16,17 While the effects of thrombin at high concentrations have been well 
characterized, the molecular details of thrombin at low concentrations have remained an 
unresolved issue. 
 
To dissect the various mechanisms of biased PAR1-mediated signaling, we have used a 
quantitative phosphoproteomics approach. Our results demonstrate that PAR1 mediates 
all thrombin-induced phosphoregulation in ECs and that ‘classical’ and ‘peptide’ 
activation of PAR1 results in highly similar signaling.  Furthermore, thrombin at low 
concentrations initiates only limited phosphoregulation. Thrombin-mediated signaling in 
ECs is completely blocked by vorapaxar, while thrombin seems to induce biased 
activation of PAR1 in presence of parmodulin-2. Finally we show that, in contrast to the 
non-canonical PAR1 TL peptides, only canonical PAR1 cleavage by thrombin generates 
a TL that potently induces early signaling in ECs. 
 
Materials and Methods 
Materials and Methods are available in the online-only Supplement 
 
Results 
Vorapaxar and parmodulin-2 completely block thrombin-mediated endothelial barrier 
disruption  
PAR1 inhibitors vorapaxar and parmodulin-2 were used to determine the role of PAR1 in 
the thrombin-induced effects in ECs. First, we determined their effect on thrombin-TL 
peptide-mediated platelet aggregation. Both PAR1 inhibitors completely inhibited 
thrombin-TL peptide-mediated platelet aggregation, with IC50 values (vorapaxar: (2 ± 1 × 
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10-8 M (mean ± standard deviation (sd)), parmodulin-2: 7 ± 1 × 10-6 M) close to their 
reported IC50 values15,30 (Figure 1A). Next, specificity of both inhibitors for blocking 
PAR1-mediated platelet aggregation was confirmed (Figure 1B). Thrombin-TL peptide-
mediated platelet aggregation was specifically blocked, while PAR4 peptide- and 
U46619-mediated platelet aggregation were unaffected. Next, PAR1 inhibitors were 
used to determine the contribution of PAR1 in thrombin-induced endothelial barrier 
disruption by Electric Cell-substrate Impedance Sensing system. Vorapaxar and 
parmodulin-2 completely inhibited thrombin-induced endothelial barrier disruption, with 
IC50 values close to those for blocking thrombin-TL peptide-mediated platelet 
aggregation (vorapaxar: 2 ± 1 × 10-8 M, parmodulin-2: 2 ± 1 × 10-6 M (Figure 2A,B,C). In 
addition, the role of other receptors than PAR1 in the thrombin-mediated endothelial 
barrier disruption was determined. Thrombin-mediated endothelial barrier disruption was 
completely blocked by vorapaxar, even at a thrombin concentration of 100nM (Figure 
2D, E). Taken together, these data show that PAR1 inhibitors completely block 
thrombin-mediated endothelial barrier disruption. 
 
Quantitative phosphoproteomics of thrombin and PAR1 stimulated ECs 
To determine the contribution of PAR1 and other receptors in the thrombin-induced 
signaling in ECs, we used a quantitative phosphoproteomics approach. To this end 
phosphoregulation by thrombin at high (10 nM) and low (50 pM) concentrations was 
compared with phosphoregulation by thrombin-TL peptide. In addition, the effects of 
PAR1 inhibitors vorapaxar and parmodulin-2 on thrombin-induced phosphoregulation in 
ECs were studied. For all these conditions, we performed a time-resolved 
phosphoproteomic analysis of stimulated Blood outgrowth endothelial cells (BOECs) by 
using a three-way reverse SILAC labeling strategy (Supplementary Figure I and 
materials and methods). Time points of stimulation were chosen based on our previous 
study of thrombin signaling.6 MS data were analyzed using the MaxQuant computational 
platform31, which identified 8306 accurately localized (class I32) phosphosites, of which 
332 (4.0%) have not been described before (PhosphoSitePlus 20 March 201733) 
(Supplementary Table I). In total 2553 phosphosites were accurately quantified, and 410 
phosphosites, localized on 268 proteins, were found to be regulated over the time-
course of our experiment (Supplementary Figure I, materials and methods and 
Supplementary Table II). The relatively low number of quantified class I phosphosites 
compared to those that were identified, can be explained by our diversity of stimulations 
(n=5) and time resolved analysis (2 time points per stimulation). To check the 
consistency of the quantified phosphosites, the thrombin/PAR1 inhibitor dataset was 
compared with our previously published thrombin dataset6 (Supplementary Figure IIA). 
Although, for reasons mentioned above, the current dataset contains a lower number of 
quantified phosphosites compared to the published thrombin dataset (2553 vs. 7793 
phosphosites), 816 new phosphosites were quantified. Notably, 87% of the thrombin-
regulated phosphosites were found to be regulated in both datasets. Due to the short 
time course of our phosphoproteomic experiment, we expected that the proteomic 
content of the BOECs did not change over the time course of the experiment.6  
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Thrombin and thrombin-TL peptide induce highly similar phosphoregulation 
To compare the phosphoproteomic changes induced by the five stimulation conditions, 
we performed a principal component analysis of the quantified phosphosites. The 
phosphoproteomes of ECs stimulated with 10 nM thrombin and thrombin-TL peptide 
clustered together and were clearly distinct from the those of ECs stimulated with 10 nM 
thrombin in the presence of vorapaxar or parmodulin-2 and ECs stimulated with 50 pM 
thrombin (Figure 3A). Next, temporal phosphoregulation of the 5 stimulation conditions 
was analyzed by hierarchical clustering of the regulated phosphosites (Figure 3B). This 
revealed that most phosphoregulation was induced by 10 nM thrombin and thrombin-TL 
peptide, followed by 10 nM thrombin in the presence of parmodulin-2, and only limited 
phosphoregulation was induced by 10 nM thrombin in the presence of vorapaxar and in 
ECs stimulated with 50 pM thrombin (Figure 3B). Regulated phosphosites included 
phosphosites with increased (241 sites; clusters 1-3) as well as decreased abundance 
(169 sites; clusters 4-6). Remarkably, phosphoregulation by thrombin and thrombin-TL 
peptide demonstrated a high degree of similarity, in terms of phosphorylation site, 
phosphorylation or dephosphorylation status as well as temporal profile. This similarity 
was further supported by the Pearson correlation of the SILAC ratios (log2) (Figure 3C). 
The appearance of minor differences between the impact of thrombin and thrombin-TL 
peptide were analyzed, however no apparent differences in phosphoregulation were 
found. All together, these data show that thrombin and thrombin-TL peptide induce 
highly similar phosphoregulation. To study the thrombin concentration-dependent 
activation of PAR1, we compared phosphoregulation by thrombin at high (10 nM) and 
low (50 pM) concentrations. In sharp contrast to the extensive phosphoregulation by 
thrombin at high concentrations (279 regulated phosphosites, localized on 201 proteins), 
at low concentrations thrombin only induced limited phosphoregulation (Supplementary 
Figure III). Although we cannot rule out that that the effects of low thrombin occur on a 
different time scale (hours), little evidence was found for biased PAR1 signaling by 
thrombin at low concentrations. 
 
Vorapaxar and parmodulin-2 demonstrate distinct antagonist properties for PAR1  
To exclude potential direct side-effects of PAR1 inhibition on ECs, we determined the 
effect of vorapaxar and parmodulin-2 on the EC steady state (phospho)proteome. We 
found no apparent changes in ECs at the (phospho)proteome level after 1 hour of pre-
incubation with vorapaxar or parmodulin-2 (Supplementary Tables III,IV), indicating that 
PAR1 inhibition alone does not induce (short term) protein expression differences nor 
initiate signaling in ECs. Next, we determined the effect of both PAR1 inhibitors on 
thrombin-induced endothelial signaling. Vorapaxar almost completely blocked the 
extensive phosphoregulation by thrombin in ECs, whereas parmodulin-2 showed partial 
inhibition (Figure 3B and Supplementary Table II). To further dissect this observed 
differential antagonistic property, the phosphosites that were still regulated by thrombin 
in the presence of one or both PAR1 inhibitors (remaining regulated phosphosites) were 
analyzed (Figure 4). This showed that vorapaxar and parmodulin-2 differentially inhibit 
thrombin-mediated signaling (35 vs 100 remaining regulated phosphosites, 
respectively). Remaining regulated phosphosites in presence of vorapaxar mainly 
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showed opposing phosphoregulation compared to thrombin alone (Figure 4A), while 
those that remained regulated in presence of parmodulin-2 mainly resembled thrombin-
mediated phosphoregulation (Figure 4B). Notably, the latter mainly concerned 
dephosphorylation events. In order to provide insight into pathways which were blocked 
by the PAR1 inhibitors, we constructed a phosphopath interaction map (Supplementary 
Figure IV). No unique pathway was revealed that was differentially affected by 
vorapaxar and parmodulin-2 (Supplementary Figure IV). However, there were clearly 
phosphosites that were completely blocked (Supplementary Figure V-A) or differentially 
blocked (Supplementary Figure V-B) by the PAR1 inhibitors. Since it has been 
described that parmodulin-2 selectively blocks Gαq- over Gα12/13-mediated activation15, 
we reconstructed the Gαq pathway based on the interactors of Serine/threonine-protein 
kinase D1 (PRKD1) (Figure 5). This revealed that early downstream effectors of Gαq are 
completely inhibited by vorapaxar, but only partially by parmodulin-2. Remarkably, 
phosphorylation of the downstream effectors of PRKD1, including Heat shock protein 
beta-1 (HSPB1) and Rab GTPase-binding effector protein 1 (RABEP1) was completely 
inhibited by both PAR1 inhibitors, while phosphorylation of Catenin delta-1, another 
potential downstream target of PRKD1 showed differential inhibition. Thrombin-specific 
phosphorylation of the transcription factor Signal transducer and activator of 
transcription 3 (STAT3) on Ser-72734 was completely inhibited by both PAR1 inhibitors 
(Supplementary Figure V-A). Taken together, these data indicate that most, if not all, 
thrombin-mediated signaling in ECs is dependent on PAR1 activation and that PAR1 
inhibitors vorapaxar and parmodulin-2 show differential antagonistic properties which 
results in biased activation of PAR1 by thrombin.  
 
In contrast to thrombin-TL peptide, PR3-TL peptide, MMP1-TL peptide, NE-TL peptide 
and APC-TL peptide do not potently induce early signaling in ECs 
To study biased activation of differential PAR1 cleavage, we initially set out to study 
phosphoregulation by APC. APC is formed after cleavage of the zymogen protein C by 
thrombin35, therefore hirudin is needed in all experiments to block residual thrombin.16,36 
Surprisingly, in our experimental conditions hirudin itself had a stronger effect on EC 
phosphoregulation than APC (Supplementary Figure VI), preventing reliable 
phosphoproteomic analysis. Notably, activation of sphingosine 1-phosphate receptor 1 
by SEW2871, which has been described to induce an increased endothelial barrier 
function37, showed distinct phosphoregulation (Supplementary Figure VI). Therefore, to 
study biased activation resulting from non-canonical cleavage of PAR1 by APC at Arg-
46 we used the TL peptide that resembles APC cleavage of PAR1, and compared this 
with phosphoregulation by thrombin-TL peptide.18 In addition, we took the opportunity to 
study biased activation of PAR1 by using the TL peptides that resemble PAR1 cleavage 
by PR3, MMP1 and NE, which have been shown to mimic the activation of PAR1 by the 
corresponding protease (Figure 6A, B).19,20 For these five TL peptides we performed a 
time-resolved phosphoproteomic analysis of stimulated BOECs (materials and 
methods). MS data were analyzed as described before, resulting in the identification of 
9324 accurately localized (class I32) phosphosites, of which 477 (5.1%) have not been 
described before (PhosphoSitePlus 20 March 201733) (Supplementary Table V). In total 
2319 phosphosite were quantified in both experiments, and 274 phosphosites, localized 
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on 194 proteins, were found to be regulated in both experiments (materials and 
methods, Supplementary Table VI). Despite the different time points of stimulation 
between the thrombin/PAR1 inhibitor dataset and the TL peptides dataset, the identified 
phosphosites show a large similarity (Supplementary Figure IIB). In contrast to thrombin-
TL peptide, the non-canonical PAR1 TL peptides only induced limited early 
phosphoregulation (Figure 6C). Moreover, sites that were found to be regulated were 
surprisingly similar for each non-canonical TL peptide, and mostly resembled the 
phosphorylation pattern of thrombin-TL peptide. Only a limited number of phosphosites 
showed opposing phosphoregulation by the non-canonical PAR1 TL peptides compared 
to thrombin-TL peptide (Figure 6D). In conclusion, these data show that the TL peptide 
that is formed after canonical cleavage of PAR1 by thrombin potently induces early 
phosphoregulation, while non-canonical PAR1 TL peptides only showed limited 
phosphoregulation in ECs. 
 
Discussion 
Thrombin-induced endothelial signaling is mediated exclusively through PAR1 
PAR1 is the predominant thrombin receptor on ECs, however it has remained unclear 
whether PAR1 alone accounts for all thrombin effects in ECs. Dissecting the contribution 
of PAR1 in thrombin-signaling in ECs is particularly relevant since PAR1 has become a 
therapeutic target for anti-thrombotic therapies. Here, we show that both orthosteric and 
allosteric PAR1 inhibitors not only specifically block thrombin-TL peptide-mediated 
platelet aggregation (Figure 1) and thrombin-mediated EC activation (Figure 2), but also 
block thrombin-induced signaling in ECs, albeit to a different extent (Figure 3). It has 
been shown that thrombin at high concentrations can directly activate PAR27. However, 
we showed that in BOECs the thrombin-mediated endothelial barrier disruption is 
completely dependent on PAR1 activation (Figure 2D-E), suggesting that the specificity 
of thrombin may be context dependent. Using a complementary approach we compared 
the possible biased activation of thrombin-TL peptide and thrombin cleavage of PAR111. 
We showed that ‘classical activation’ of PAR1 by thrombin and ‘peptide activation’ by 
thrombin-TL peptide induce highly similar phosphoregulation in ECs (Figure 3), which  
implies that despite the difference in affinity of the tethered ligand formed after thrombin 
cleavage and the soluble thrombin-TL peptide23, similar signaling networks are 
activated. Taken together, our system-wide phosphoproteomics approach reveals that 
most, if not all, thrombin-mediated signaling in ECs is dependent on PAR1.  
 
Mechanistically distinct PAR1 inhibitors induce biased signaling 
Orthosteric PAR1 inhibitors (vorapaxar, atopaxar) have been shown to increase the risk 
of bleeding, a side effect which has been linked to global inhibition of PAR1 on cells 
other than platelets, most notably ECs.27 In the quest for a PAR1 antagonist that 
prevents coagulation without promoting bleeding, several allosteric PAR1 inhibitors have 
been developed that bind to the intracellular side of the receptor (pepducins28,29 and 
parmodulins14,15). For parmodulin-2, it has been postulated that it promotes biased 
PAR1 signaling by preferentially blocking Gαq- over Gα12/13-mediated PAR1 signaling.15 
However, it remained unknown how parmodulin-2 blocks these different signaling 
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networks. We found that vorapaxar and parmodulin-2 differentially inhibit thrombin-
induced phosphoregulation (Figure 3). On the one hand, vorapaxar blocked virtually all 
thrombin-induced phosphoregulation in ECs, supporting the hypothesis that thrombin-
induced phosphoregulation in ECs is dependent on PAR1 activation, while on the other 
hand, parmodulin-2 showed only partial inhibition (Figure 3, 4). Notably, these remaining 
regulated phosphosites mostly contained phosphosites with a decreased abundance, 
suggesting that parmodulin-2 may be unable to block a thrombin-activated phosphatase. 
Phosphopath network analysis of the remaining regulated phosphosites showed that, 
despite the fact that there were phosphosites that were completely or differentially 
blocked (Supplementary Figure V), there was not one uniquely affected pathway 
(Supplementary Figure IV). However, detailed analysis of the Gαq-mediated 
phosphorylation downstream of PRKD1 revealed that these processes were 
differentially inhibited (Figure 5, Supplementary Figure V). The early effectors 
downstream of Gαq are all completely inhibited by vorapaxar, whereas parmodulin-2 
completely inhibits phosphorylation of 1-phosphatidylinositol 4,5-bisphosphate 
phosphodiesterase gamma-1 (PLCG1), but only partially inhibits phosphorylation of 
PLCB3 and PRKD1 (Figure 5). These phosphosites include Ser-537 on PLCB3, which is 
located in the X-Y linker of PLCB3 that is close to the N-terminus coiled-coil domain of 
PLCB3 and the N-terminus of Gαq  in the crystal structure of the complex.38 The location 
of this phosphosite suggests a link to activation of PLCB3 and would imply that PLCB3 
activation is completely inhibited by vorapaxar and only partially by parmodulin-2. Some 
of the downstream effectors and the kinase-substrate related phosphosites downstream 
of PRKD1 are completely inhibited by both PAR1 inhibitors, while the dephosphorylation 
of Catenin delta-1, an interesting potential downstream target of PRKD139,40, is 
differentially inhibited. Thrombin-specific phosphorylation of STAT3 on Ser-72734 is 
completely inhibit by both PAR1 inhibitors (Figure 6B), which suggests that STAT3-
mediated gene regulation is completely blocked. Taken together, vorapaxar and 
parmodulin-2 demonstrate distinct antagonistic properties for PAR1 on ECs. Our data 
corroborate the finding by Aisiku et al15 that parmodulin-2 seems to induce biased 
activation of PAR1 by thrombin. However, from our data it seems that biased activation 
of PAR1 in presence of parmodulin-2 is much more complex and not solely linked to a 
specific G-protein downstream of PAR1. 
 
Biased activation of PAR1: canonical versus non-canonical cleavage 
To determine biased activation of PAR1 on ECs, we compared the phosphoregulation 
induced by thrombin at low and high concentrations as well as by the canonical 
thrombin-TL peptide and the non-canonical TL peptides PR3-TL, MMP1-TL, NE-TL and 
APC-TL. In contrast to our expectations, these four non-canonical PAR peptides only 
showed limited early phosphoregulation (Figure 6) which was highly similar and mostly 
resembled thrombin-TL peptide-mediated phosphoregulation. This seems to be at 
variance with their hypothesized induction of biased signaling18–20. In addition, our data 
revealed only limited phosphoregulation by thrombin at low concentrations 
(Supplementary Figure V). Strikingly, the few phosphosites that remained regulated 
under these conditions mostly overlapped with those that were regulated by thrombin at 
high concentrations, suggesting that they represent the most thrombin-sensitive 
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phosphosites (Supplementary Figure V). The same was true for the remaining regulated 
phosphosites in presence of parmodulin-2, which explains the appearance of overlap in 
the principal component analysis (Figure 3A). In contrast, phosphosites that remained  
regulated in presence of vorapaxar mainly showed opposing phosphoregulation. Beta-
arrestin-mediated phosphoregulation by PAR1 has been described to play a role in the 
signal transduction of APC.22 In our dataset we identified one phosphosite on beta-
arrestin-1, Ser-412, which has been described in the activation of the GPCR 5–HT4R.41 
However, this phosphosites was not regulated in any of the stimulation conditions during 
the time course of our experiments. Since we only analyzed the signaling transduction in 
ECs in the first 10-20 minutes, and the barrier-protective effects of thrombin and APC 
have been shown to occur on a longer time-scale (hours)16–18,36, we may not have 
covered the barrier-protective phosphoregulation nor the beta-arrestins-dependent 
biased activation of PAR1. In addition, we cannot rule out that functional assays with 
respect to PAR1-mediated barrier protective effects are more sensitive than our 
phosphoproteomics approach.  
 
PAR1 inhibition: more than platelets 
Here, we show that the FDA approved PAR1-directed antiplatelet drug vorapaxar 
virtually inhibits all thrombin-induced signaling in ECs. Notably, the vorapaxar 
concentration used in our study (100 nM) lies within the range of steady state plasma 
levels observed in healthy individuals during phase I clinical trials.42 In view of the 
putative protective role of PAR1 in maintaining endothelial barrier integrity, our data 
provide an possible explanation for the increased bleeding tendency of this drug.27 
Given the crucial role of endothelial PAR1, our study implies that phosphoproteomic 
studies may help in the drug design process by identifying the effects of PAR1 directed 
anti-platelet drugs in the endothelium, in a similar way as the use of quantitative mass 
spectrometry for profiling of kinase inhibitors.43 Besides the role of PAR1 in coagulation, 
PAR1 has been linked to various other (patho)physiological conditions, including 
gastrointestinal and central nervous system diseases and cancer.44 Within these diverse 
environments, PAR1 has also been studied as a drug target, as reviewed by 
Ramachandran et al44 Surprisingly, PAR1 has been identified as important marker for 
retention and recruitment of endothelial protein C receptor-expressing bone marrow 
hematopoietic stem cells.45 In addition, diplopia has been observed in patients taking 
vorapaxar, showing the crucial role of PARs in the eye.46 In summary, given the multiple 
signal pathways triggered by PAR1 in diverse tissues, it will be a challenge to design a 
PAR1 antagonist that will target only those pathways responsible for tissue pathology. 
 
Future directions 
Here, we have shown that thrombin signals to ECs exclusively through PAR1. Other 
serine proteases of the coagulation cascade, like Factor VIIa and Factor FXa target not 
only PAR1 but also PAR2.47,48 In addition, both PAR1 and PAR4 are important for 
thrombin-mediated platelet aggregation.49 While it has been described that PAR1, PAR2 
and PAR4 activation can be linked to overlapping and distinct activation of G proteins 
and functional outcome50–52, to what extent all PARs induce similar signaling pathways 
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is a subject for further studies. In addition, it remains an open question to what extent 
feed-forward signaling by thrombin-induced secreted agonist or proteins (including 
matrix metalloproteases53,54 and sphingosine 1-phosphate16) contributes to the 
thrombin-induced signal transduction pathways. Unraveling the PAR-induced signaling 
pathways will help in dissecting the intimate interplay of the coagulation cascade and the 
vessel wall. This will aid in the understanding of PARs as a therapeutic target in the 
treatment of cardiovascular diseases, hemostatic disorders and cancer.  
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Highlights 
 Thrombin signaling in endothelial cells is mediated exclusively via PAR1 
 ‘Classical’ and ‘peptide’ activation of PAR1 initiate highly similar signaling 
pathways 
 The recently FDA- approved orthosteric PAR1-directed anti-platelet drug 
vorapaxar and the allosteric PAR1 inhibitor parmodulin-2 reveal differential 
antagonistic properties 
 In contrast to peptides that mimic non-canonical cleavage of PAR1, only the 
tethered ligand peptide that mimics canonical cleavage of PAR1 by thrombin 
potently induces early signaling in ECs 
 
 
Figure legends 
Figure 1. Vorapaxar and parmodulin-2 specifically inhibit thrombin-TL peptide-mediated 
platelet aggregation.(A) Platelets were pre-incubated for 10 minutes with indicated 
concentrations of vorapaxar, parmodulin-2, or vehicle (DMSO), followed by triggering 
platelet aggregation with 10 µM thrombin-TL peptide (SFLLRN-NH2). Normalized 
response was calculated per sample by normalizing the maximal aggregation to the 
maximal aggregation in the vehicle control. Data and IC50 values represent mean ± sd 
(n=3). IC50 values were calculated using “log(inhibitor) vs. normalized response -- 
Variable slope” (Graphpad Prism version 6.04). (B) Specificity of vorapaxar and 
parmodulin-2 for blocking thrombin-TL peptide-mediated platelet aggregation was 
determined. Platelets were pre-incubated for 10 minutes with indicated concentrations of 
vorapaxar, parmodulin-2, or vehicle (DMSO), followed by triggering platelet aggregation 
with the following agonists: thrombin-TL peptide (10 µM), PAR4 peptide (AYPGKF-NH2) 
(150 µM), collagen (2 µg/ml) or thromboxane A2 receptor agonist U46619 (5 µM). Data 
represent mean ± sd (n=3), * P < .05, *** P < .001 by two-way ANOVA with post hoc 
Tukey’s multiple comparison test (Graphpad Prism version 6.04). 
 
Figure 2. Vorapaxar and parmodulin-2 completely inhibit thrombin-induced endothelial 
barrier disruption. (A, B) BOECs were pre-incubated for 1 hour with indicated 
concentrations of vorapaxar (A), parmodulin-2 (B), or vehicle control (DMSO), followed 
by stimulation with 10 nM thrombin (1U/ml thrombin = 10 nM). Representative tracings 
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of transendothelial electrical resistance after addition of thrombin (t = 0 hours) are 
shown. Values were normalized per sample to the resistance 9 minutes prior to addition 
of thrombin. Experiments were performed in duplicates. (C) Effect of vorapaxar and 
parmodulin-2 on thrombin-induced endothelial barrier disruption. Normalized response 
was calculated per sample by normalizing the minimal resistance after thrombin addition 
to the minimal resistance after thrombin addition in the vehicle control. Data and IC50 
values represent mean ± sd (n=3). IC50 values were calculated using “log(inhibitor) vs. 
normalized response -- Variable slope” (Graphpad Prism version 6.04). (D) BOECs were 
pre-incubated for 1 hour with indicated concentrations of vorapaxar or vehicle control 
(DMSO), followed by stimulation with the indicated concentrations of thrombin (1U/ml 
thrombin = 10 nM). Values were normalized per sample to the resistance 9 minutes prior 
to addition of thrombin (t = 0 hours). Data represent mean ± sd (n=3). (E) Effect of 
vorapaxar pre-incubation on thrombin-mediated endothelial barrier disruption. Data as in 
D, endothelial barrier disruption was calculated per sample by calculating the minimal 
resistance after thrombin addition. Data represent mean ± sd (n=3).  
 
Figure 3. Thrombin and thrombin-TL peptide induce highly similar temporal 
phosphoregulation. (A) Two components that capture 43.7% of the total variance of the 
BOEC phosphoproteome changes during the 5 different stimulation conditions 
(Thrombin alone (10 nM or 50 pM); thrombin-TL peptide; and 10 nM thrombin in the 
presence of either vorapaxar or parmodulin-2 (see legend)) are shown. Principal 
component analysis was performed on the quantified SILAC ratios (n=2553). Replicates 
of both time points are shown per stimulation condition. Replicates of thrombin and 
thrombin-TL peptide cluster together, indicated by sphere. (B) Heat map and 
hierarchical clustering (based on average euclidean distance and preprocessed with k-
means) based on the SILAC log2 ratio of the regulated phosphosites (n=410). The 6 
clusters discriminate between phosphosites with increased (clusters 1-3) and decreased 
abundance (clusters 4-6). Heatmap colors (see legend) are based on the SILAC log2 
ratios reported in Supplementary Table II. (C) Correlation plots and heatmap of Pearson 
correlation coefficients of Thrombin and thrombin- TL peptide stimulated BOECs. 
Pearson correlation coefficients were calculated for each replicate and time point, and 
were based on the SILAC log2 ratios of the regulated phosphorylation sites (n=410). 
Correlation plots (lower left half) and a heatmap of the Pearson correlation coefficients 
(top right half) are shown. Heatmap colors (see legend) are based on the Pearson 
correlation coefficient. 
 
Figure 4. Remaining regulated phosphosites reveal distinct antagonistic properties for 
vorapaxar and parmodulin-2 . Heat maps based on the SILAC log2 ratio of regulated 
phosphosites by 10 nM thrombin (1U/ml thrombin = 10 nM) in the presence of (A) 
vorapaxar (35 phosphosites) or (B) parmodulin-2 (100 phosphosites). SILAC log2 ratios 
of 10 nM thrombin alone and 10 µM Thrombin-TL peptide are also shown. Gene names 
with modified amino acid are shown on the right. The reported amino acid position refers 
to the protein within the protein group for which a reference number (referred to as 
UniProtKB) was found in the PhosphoSitePlus database. Heatmap colors (see legend) 
are based on the SILAC log2 ratios reported in Supplementary Table II; ^, redundant 
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site, _1, _2 or _3 indicates if the quantification of the phosphorylation site was based on 
singly (_1), doubly (_2), or multiply (_3) phosphorylated peptides. 
 
Figure 5.Visualization of PRDK1 interaction network. Gene names and localization of 
their phosphosites(s) are shown. A straight line visualizes protein−protein interactions 
from Biogrid, and kinase−substrate interactions from PhosphoSitePlus are visualized by 
an arrow. Proteins indicated as not-filled circles are added to the network. Dotted 
straight lines and dotted arrow are added to the network based on literature. Interaction 
network was made using the Phosphopath plug-in55 from Cytoscape.56 Graphs 
represent mean and sd for the MS-based quantifications of the indicated phosphosites 
(see Supplementary Figure I-C for N values per stimulation condition). MS-
quantifications of thrombin (10 nM), thrombin-TL peptide; and 10 nM thrombin in the 
presence of either vorapaxar or parmodulin-2 are shown. 
 
Figure 6. Only canonical PAR1 cleavage by thrombin generates a tethered ligand that 
potently induces early signaling in ECs. (A) Schematic representation of the PAR1 N-
terminus with the known cleavage sites of the proteases depicted; Neutrophil Protease 
(PR3, Ala-36), Matrix Metalloproteinase-1 (MMP1, Asp-39), Thrombin (Arg-41), 
Neutrophil Elastase (NE, Leu-45) and Activated protein C (APC, Arg-46). (B) Synthetic 
peptides that mimic the tethered ligand after cleavage of the indicated protease were 
used to mimic PAR1 activation by the corresponding protease. Starting amino acid of 
each TL peptide is indicated in A. (C) Heat map and hierarchical clustering (based on 
average euclidean distance and preprocessed with k-means) based on the SILAC log2 
ratio of regulated phosphosites in the tethered ligand activation peptides dataset 
(n=274). BOECs were stimulated with the indicated TL peptides (50 µM). Heatmap 
colors (see legend) are based on the SILAC log2 ratios reported in Supplementary Table 
VI. (D) MS-based quantifications of the indicated phosphosites, quantifications of both 
replicates are shown.   
 
 
